Epidemiology and Changing Market Dynamics of Schizophrenia in the Seven Major Markets

May 20 02:05 2021
Epidemiology and Changing Market Dynamics of Schizophrenia in the Seven Major Markets


Schizophrenia Market” report has been added to DelveInsight


Schizophrenia Overview

Schizophrenia is a serious mental illness that interferes with a person’s ability to think clearly, manage emotions, make decisions, and relate to others. It is a complex, long-term medical illness, affecting about one percent of Americans.


Schizophrenia Market

DelveInsight’s “Schizophrenia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Request free sample copy @ https://www.delveinsight.com/sample-request/schizophrenia-market-insight


Schizophrenia Market: Regions Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Schizophrenia Key Players

  • Otsuka America Pharmaceutical/Lundbeck
  • Intra-Cellular Therapies
  • Sunovion Pharmaceuticals/ Sumitomo Dainippon Pharma            
  • Merck/AbbVie/Schering-Plough Corporation/Allergan
  • Otsuka Pharmaceutical
  • Janssen Research & Development
  • And many others


Schizophrenia Drugs

  • Rexulti (brexpiprazole/OPC-34712)
  • Caplyta (lumateperone/ITI-007):
  • Latuda (lurasidone hydrochloride):
  • Saphris (asenapine):
  • Abilify MyCite (aripiprazole tablets with sensor):
  • Invega Sustenna (paliperidone palmitate):
  • Vraylar/Reagila (cariprazine):
  • And many others


Schizophrenia Market Report

Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early twenties for men, and the late twenties to early thirties for women. It is uncommon for schizophrenia to be diagnosed in a person younger than 12 or older than 40.


Schizophrenia Market Insights

Schizophrenia isn’t caused by just one genetic variation, but a complex interplay of genetics and environmental influences. While schizophrenia occurs in one percent of the general population, having a history of family psychosis greatly increases the risk. Schizophrenia occurs at roughly 10% of people who have a first-degree relative with the disorder, such as a parent or sibling.


Schizophrenia Symptoms

With medication, psychosocial rehabilitation, and family support, the symptoms of schizophrenia can be reduced. Typically, a health care provider will prescribe antipsychotics to relieve symptoms of psychosis, such as delusions and hallucinations. Due to a lack of awareness of having an illness and the serious side effects of medication used to treat schizophrenia, people who have been prescribed them are often hesitant to take them.


Schizophrenia Market Size

The increase in market size is a direct consequence of increasing prevalent population of schizophrenia patients in the 7MM, USD 7,454.97 million in 2021


Schizophrenia Treatment Market

The major medications used to treat schizophrenia are called antipsychotics. They are generally effective for treating the positive symptoms of schizophrenia. Every person reacts a little differently to antipsychotic drugs, so a patient may need to try several before finding the one that works best. If a medication does help, it is important to continue it even after symptoms get better. Without medication, there is a high likelihood that psychosis will return, and each returning episode might be worse.


Current Major Schizophrenia Treatment Options

  • Risperdal (risperidone)
  • Abilify (aripiprazole)
  • Invega Trinza/sustenna
  • Rexulti (brexpiprazole)
  • Latuda (lurasidone hydrochloride)
  • Caplyta (lumateperone)


Request free sample copy @ https://www.delveinsight.com/sample-request/schizophrenia-market-insight


Table of content

1. Key Insights

2. Executive Summary of Schizophrenia

3. Competitive Intelligence Analysis for Schizophrenia

4. Schizophrenia: Market Overview at a Glance

5. Schizophrenia: Disease Background and Overview

7. Schizophrenia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Schizophrenia Treatment

11. Marketed Products

12. Emerging Therapies

13. Schizophrenia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Schizophrenia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Schizophrenia Market Drivers

  • Increasing Awareness
  • Pipeline Advancement
  • Growing Research and development
  • Long-acting Injectable Antipsychotics


Schizophrenia Market Barriers

  • Economic Burden
  • Significant Side Effects of Approved Therapy
  • Denial of illness
  • Co-occurring medical conditions


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.




Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/